Cost-effectiveness Analysis of Neoadjuvant Immune Checkpoint Inhibition Vs. Cisplatin-Based Chemotherapy in Muscle Invasive Bladder Cancer.
Urologic Oncology Seminars and Original Investigations(2021)
Key words
Muscle invasive bladder cancer,Urothelial carcinoma,Neoadjuvant,Immunotherapy,Cost effectiveness analysis
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined